"10.1371_journal.pone.0062342","plos one","2013-04-26T00:00:00Z","Claire E Le Pichon; Sara L Dominguez; Hilda Solanoy; Hai Ngu; Nicholas Lewin-Koh; Mark Chen; Jeffrey Eastham-Anderson; Ryan Watts; Kimberly Scearce-Levie","Department of Neuroscience, Genentech Inc., South San Francisco, California, United States of America; Department of Pathology, Genentech Inc., South San Francisco, California, United States of America; Department of Nonclinical Biostatistics, Genentech Inc., South San Francisco, California, United States of America","Conceived and designed the experiments: CELP RW KSL. Performed the experiments: CELP SLD HS MC. Analyzed the data: CELP HN NLK JEA. Wrote the paper: CELP KSL.","All authors were employees of Genentech, Inc. at the time this work was completed, whose company funded this study. The drug used in the study, erlotinib, is marketed for the treatment of non-small cell lung carcinoma under the brand name TarcevaÂ®. There are no further patents, products in development or marketed products to declare. This does not alter the authors' adherence to all the PLOS ONE policies on sharing data and materials.","2013","04","Claire E Le Pichon","CELP",9,TRUE,3,4,4,2,TRUE,TRUE,FALSE,0,NA,FALSE
